House Dust Mite Extract, from D.pteronyssinus

House Dust Mite Extract, from D. pteronyssinus 是一种来源于 Dermatophagoides pteronyssinus 的屋尘螨致敏提取物,可使血清 IgE、IgG1、IgG2a 水平升高,并提高白细胞介素 (Interleukin) 4、5、6、10、13、17 的水平,诱导显著的哮喘病理改变,可用于哮喘和变应性结膜炎的相关研究。
House Dust Mite Extract, from D.pteronyssinus
产品编号: MS-A73836
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
600μg
询价
3-5 天

产品描述

House Dust Mite Extract, from D. pteronyssinus 是一种来源于 Dermatophagoides pteronyssinus 的屋尘螨致敏提取物,可使血清 IgE、IgG1、IgG2a 水平升高,并提高白细胞介素 (Interleukin) 4、5、6、10、13、17 的水平,诱导显著的哮喘病理改变,可用于哮喘和变应性结膜炎的相关研究。

生物实验数据

生物活性 House Dust Mite Extract, from D. pteronyssinus is a house dust mite allergenic extract derived from Dermatophagoides pteronyssinus that elevates serum IgE, IgG1, and IgG2a levels, increases the levels of Interleukin 4, 5, 6, 10, 13, and 17, induces significant asthmatic pathological changes, and can be used for research related to asthma and allergic conjunctivitis.
IC50 & Target

IL-6

 

IL-5

 

IL-4

 

IL-10

 

IL-13

 

IL-17

 

体内研究
(In Vivo)

House Dust Mite Extract from D.pteronyssinus (100 μg/mL;雾化;每次给 10 分钟;于第 7、14、21、28、35、42、60、61 天共给 8 次) 可在雄性 BALB/c 小鼠中诱导显著的哮喘病理改变,包括气道高反应性升高、炎症细胞浸润、免疫球蛋白产生、细胞因子释放、支气管增厚、胶原沉积及 MUC5AC 表达上调,上述所有指标均显著高于 PBS 对照组水平。
House Dust Mite Extract, 提取自 D.pteronyssinus (10-500 μg;腹腔注射;吸附于 2.0 mg 氢氧化铝上) 可诱导 BALB/c 小鼠发生过敏性结膜炎,其中 10 μg 为最佳腹腔致敏剂量,可使总 IgE 水平、IL-5 产生量及结膜内胞内表达 IL-5 的 CD4+ST2+ T 细胞占比达到最高。

Animal Model: BALB/c (male, 5-week-old)
Dosage: 100 μg/mL
Administration: nebulization; 10 minutes per administration; 8 total administrations on Days 7, 14, 21, 28, 35, 42, 60, 61
Result: Showed significantly higher airway hyperresponsiveness (Penh V) than PBS control at all tested methacholine concentrations (3.1, 6.25, 12.5, 25, 50 mg/mL).
Increased total cell, eosinophil, neutrophil, lymphocyte, and macrophage counts in bronchoalveolar lavage fluid compared to PBS control (P < 0.01).
Elevated serum IgE, IgG1, and IgG2a levels compared to PBS control (P < 0.05).
Increased bronchoalveolar lavage fluid levels of IL-4, IL-5, IL-6, IL-10, IL-13, and IL-17 compared to PBS control (P < 0.05).
Increased splenocyte levels of IL-4, IL-5, IL-6, IL-10, IL-13, and IL-17 compared to PBS control (P < 0.05).
Caused significantly thicker bronchial mucosa, increased collagen deposition, and higher percentage of PAS-positive cells in lung tissue compared to PBS control (P < 0.01).
Increased MUC5AC protein and mRNA expression in lung tissue compared to PBS control (P < 0.01).
Animal Model: BALB/c (female, 8-week-old, allergic conjunctivitis model via intraperitoneal sensitization followed by topical ocular challenge)
Dosage: 10 μg (i.p. sensitization); 100 μg (i.p. sensitization); 500 μg (i.p. sensitization); 500 μg (topical ocular challenge)
Administration: i.p.; days 1 and 8; absorbed on 2.0 mg aluminum hydroxide; topical instillation in each eye; days 15, 17, 19
Result: Exhibited mean clinical scores of 6 to 7, with symptoms including eye frowning, discharge, and hyperemia (no significant difference between HDM groups).
Showed significantly elevated total serum IgE levels: ~800 ng/mL (10 μg i.p.
group), ~350 ng/mL (100 μg group), ~250 ng/mL (500 μg group), compared to controls.
Displayed significantly elevated HDM-specific IgE (OD 450 nm): ~0.6 (10 μg group), ~0.4 (100 μg group), ~0.3 (500 μg group), compared to controls.
Increased cervical lymphocyte proliferation after HDM stimulation: S-phase lymphocyte populations rose from 4.7% to 13.2% (10 μg group), 3.2% to 11.5% (100 μg group), and 3.3% to 12.5% (500 μg group); S-phase CD4+ T-cell populations rose from 5.0% to 11.7% (10 μg group), 1.4% to 3.3% (100 μg group), and 3.4% to 15.5% (500 μg group).
Showed significantly elevated IL-4 and IL-5 levels in cervical lymphocyte supernatants after HDM stimulation; IL-5 levels reached ~45 pg/mL in the 10 μg group, significantly higher than other HDM groups.
Induced significant conjunctival infiltration of eosinophils (~6-8 cells per slide) and mast cells (~10-14 cells per slide) compared to controls.
Had the highest proportion of conjunctival CD4+ST2+ T cells (17.1%) and the highest proportion of these cells with intracellular IL-5 (82.4%) in the 10 μg group, significantly elevated compared to controls.
性状 固体
颜色 Light brown to brown

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础